Table 1.
Total Renal Excretion During 1‐Week Periods of Diuretic Administration
| Parameter | Dapagliflozin (Day 1–7) | Bumetanide (Day 1–7) | Dapagliflozin and Bumetanide (Day 1–7) | Dapagliflozin and Bumetanide (Day 8–14) |
|---|---|---|---|---|
| Volume, mL·wk−1 | 16 082±2146 | 16 445±1612 |
20 033±1983 (P<0.05 vs dapagliflozin or bumetanide alone) |
16 272±1567 |
| Glucose, g·wk−1 | 239±20 | 0.3±0.06 |
188±20 (P<0.05 vs bumetanide) |
150±19 (P<0.05 vs bumetanide) |
| Na+, mmol·wk−1 | 625±15 | 669±46 |
723±28 (P<0.05 vs dapagliflozin alone) |
742±19 (P<0.05 vs dapagliflozin or bumetanide alone) |
| K+, mmol·wk−1 | 415±24 | 454±32 |
514±35 (P<0.05 vs dapagliflozin alone) |
442±28 |
| Urate, mg·wk−1 | 3382±187 | 2249±160 |
3163±211 (P<0.05 vs bumetanide alone) |
2598±160 |
| Ca++, mg·wk−1 | 597±76 | 667±54 | 646±33 | 707±40 |
| Mg++, mg·wk−1 | 548±37 | 613±48 | 611±42 | 552±52 |
Data are given as mean±SEM values for total renal excretion over 1 week of dapagliflozin, bumetanide, or combined therapy, and during the second week of combined therapy.